24.11
-0.26(-1.07%)
Currency In USD
| Previous Close | 24.37 |
| Open | 24.48 |
| Day High | 24.53 |
| Day Low | 23.51 |
| 52-Week High | 46.5 |
| 52-Week Low | 18.41 |
| Volume | 2.97M |
| Average Volume | 2.2M |
| Market Cap | 2.32B |
| PE | -4.07 |
| EPS | -5.93 |
| Moving Average 50 Days | 31.7 |
| Moving Average 200 Days | 32.68 |
| Change | -0.26 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $292.95 as of January 14, 2026 at a share price of $24.11. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $172.37 as of January 14, 2026 at a share price of $24.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 12:30 PM GMT
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivota
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
Dec 30, 2025 9:05 PM GMT
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIaNOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submissio